Mandate

Vinge advises Calliditas in connection with a directed share issue

The Board of Directors of Calliditas Therapeutics AB (publ) (“Calliditas”) has resolved on a directed new issue of shares, whereby the company will raise proceeds of approximately SEK 210 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Carnegie Investment Bank and Zonda Partners.

Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the company can partially or completely participate in the commercialization efforts. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin and Edin Agic.

Related

Vinge has advised Sertion AB in connection with the acquisition of Svensk Anläggning och Driftteknik AB

Through the acquisition, Sertion takes a further step in its development as a leading international infrastructure and installation group within complex HVAC systems, technical infrastructure, and industrial piping. Svensk Anläggning och Driftteknik AB specializes in certified welding and installation of industrial piping.
February 10, 2026

Vinge advises Mirova in connection with the acquisition of the Boarp, Dållebo and Fågelås wind farms

Vinge has advised Mirova, a subsidiary of Natixis Investment Managers focusing on sustainable investments, in connection with the acquisition of the three Swedish onshore wind farms Boarp, Dållebo and Fågelås.
February 10, 2026

Vinge has advised Bridgepoint in its acquisition together with Polaris of a majority stake in PDSVISION, a global leader in digital engineering

Headquartered in Stockholm, PDSVISION operates across North America, Europe and Asia. The company delivers integrated software and services that support digital transformation in product development and manufacturing, helping customers improve productivity and accelerate the journey from concept to production. The company has built a subscription-led business with ~SEK 1.7 billion in revenues, characterised by longstanding customer relationships and strong organic growth.
February 10, 2026